It feels great when an Indian pharmaceutical company i.e. Ranbaxy
Laboratories has announced that its subsidiary, Ranbaxy Australia has launched
Atrovastatin in 10mg, 20mg, 40mg, 80mg in Australian market. This has been
approved from Therapeutic Goods Administration, the regulatory authority in Australia. The
brand was introduced under the name, ‘Trovas’ through retail pharmacy chains.
Basically Atrovastatin is a cholesterol reducing drug and it is the most prescribed
medicine in Australian pharmacy market. Atorvastatin is the largest selling
pharmaceutical product in Italy
with sales of US$ 377 Mn (IMS MAT Dec., 2011). The market size for Atorvastatin
in the Netherlands is US$ 164.4 Mn (IMS MAT Dec., 2011) and in Sweden
is US$ 55 Mn (IMS MAT Dec., 2011) and is the largest selling Statin product in
these two markets.
Alex Evans, Managing Director Ranbaxy Australia, said that Ranbaxy is the first Indian
generic company in Australia
to introduce Atrovastatin under the brand name, ‘Trovas’. The continent is
important strategic market for Ranbaxy, which entered in Australian market in
2006. Australia
has distinct business philosophy committed to empowering community pharmacies
and improving access to quality medicines. Ranbaxy Laboratories Limited,
India's largest pharmaceutical company, is an integrated, research based,
international pharmaceutical company producing a wide range of quality,
affordable generic medicines, trusted by healthcare professionals and patients
across geographies. Ranbaxy's continued focus on R&D has resulted in
several approvals, in developed and emerging markets many of which incorporate
proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at
its own labs. The company has further strengthened its focus on generics
research and is increasingly working on more complex and specialty areas.
Ranbaxy serves its customers in over 125 countries and has an expanding
international portfolio of affiliates, joint ventures and alliances, ground
operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy
is a member of the Daiichi Sankyo Group. Through strategic in-licensing
opportunities and its hybrid business model with Daiichi Sankyo, a leading
global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing
many innovator products in markets around the world, where it has a strong
presence.
YASH SHRIVASTAVA
MARKETING EXECUTIVE
BIOINFORAMATICS INSTITUTE OF INDIA
Posts
